Aesculap receives FDA clearance for SterilContainer product line for use in STERIS V-PRO systems

NewsGuard 100/100 Score

Aesculap, Inc. is pleased to announce that the SterilContainer S product line has been cleared by the United States Food and Drug Administration (FDA), (510(k) number, K093649) for use in the STERIS Corporation's V-PRO 1 and V-PRO 1 Plus Low Temperature Sterilization Systems.

“Healthcare facilities can reduce repair cost while maximizing set utilization by securing heat and moisture-sensitive instruments in the Aesculap SterilContainer S system during processing in the V-PRO™ 1 and V-PRO™ 1 Plus Systems.”

"Maximizing ROI is key in today's economic environment," said Edward Nuber, Product Manager, Sterile Technology, Aesculap Inc. "Healthcare facilities can reduce repair cost while maximizing set utilization by securing heat and moisture-sensitive instruments in the Aesculap SterilContainer S system during processing in the V-PRO™ 1 and V-PRO™ 1 Plus Systems."

The Aesculap SterilContainer S is a reusable, environmentally friendly, rigid container system used for the packaging, transportation, and storage of instruments prior to, during and after sterilization. The SterilContainer S product line consists of Full, Three Quarter, Half and Extra Long Mini size SterilContainers, instrument baskets, filters, indicator cards, tamper proof locks, silicone mats, and the Aesculap Instrument Organization System.

The V-PRO 1 and V-PRO 1 Plus Low Temperature Sterilization Systems can quickly process high volumes of heat and moisture-sensitive devices using vaporized hydrogen peroxide, an environmentally friendly sterilant. In addition to the single 55-minute automated cycle of the V-PRO 1 system, the new V-PRO 1 Plus sterilizer includes a second 28-minute cycle specifically for sterilizing non-lumened devices. This allows operators to enhance productivity by choosing the cycle that best matches the devices being sterilized. Both systems have a one-touch control that requires minimal training, and both are equipped with remote monitoring capabilities for increased uptime.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research sheds light on how GLP-1 obesity drugs may change food cravings